Faculty introduction, disclosures

Introductory content   Epidemiology, risk factors  Risk for underdiagnosis  Burden of disease: organ damage; distress and uncertainty; effect on quality of life   SM subtypes: clinical presentation; WHO classification criteria; evaluation of B- and C-findings

SM treatment  Goals of care  Factors impacting decision-making  Pharmacotherapy for indolent, smoldering SM  Mast cell stabilization  Symptom and complication management  Pharmacotherapy for advanced SM  Treatment options  Tyrosine kinase inhibition  Second and later-line therapy  Cladribine  Interferon  Other agents  Efficacy and safety data  Treatment selection and sequencing  Monitoring and evaluating treatment response: Mayo criteria, IWG-MRT-ECNM, changes based on new treatment options  Patient education: avoiding triggers; recognizing and managing anaphylaxis  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Describe the clinical presentation and diagnostic criteria of systemic mastocytosis, and its classification.
• Review the subtypes of advanced SM, the burden of disease, and its impact on quality of life.
• Compare the efficacy and safety of treatment options for advanced SM.
• Develop a treatment plan for a patient with advanced SM.
• Review the assessment of treatment response in advanced SM.

ACCME Activity #202557749

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Tsewang Tashi, MD, Associate Professor, Division of Hematology & Hematologic Malignancies, University of Utah, has received financial compensation from Blueprint Medicines, PharmaEssentia, Cogent Biosciences for consulting and/or advisory board activities.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Blueprint Medicines. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version